BIND, Amgen collaborate on solid tumor drug development

01/9/2013 | American City Business Journals

Amgen and BIND Biosciences agreed to develop a drug for solid tumors using the latter's technology platform. The partners hope to develop a new class of drug that would be more effective and less toxic than existing chemotherapy treatments. BIND could potentially receive up to $180.5 million in upfront and milestone fees, plus royalties.

View Full Article in:

American City Business Journals

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director of Behavioral Health Operations
Meridian Health Plan
Detroit, MI
Medical Director
PacificSource
Bend, OR
Clinical Appeals RN
MJHS
Brooklyn, NY
Director of Clinical Operations
Meridian Health Plan
Detroit, MI
Sr. Director, Regulatory Compliance Intelligence and Outreach
Johnson & Johnson
New Brunswick, NJ